About IngenOx
IngenOx Therapeutics is a biopharma advancing a clinical and pre-clinical pipeline of precision therapies and vaccines for different cancer indications.
Executive Team
Professor Nick La Thangue
MA MSc PhD FRSE FMedSci
Chief Executive Officer
Nick has over 30 years of experience in biotech, leadership, entrepreneurship, translational cancer science and drug development. He founded Prolifix focused on cell cycle therapeutics, where he acted as CSO and CEO until its merger with TopoTarget which led to a highly successful IPO. He founded Celleron Therapeutics and Argonaut Therapeutics, acting as CEO for each company, and led their merger in 2022 to form IngenOx. He has been CEO at IngenOx Therapeutics developing precision cancer drugs since the company was formed. Nick is Professor of Cancer Biology at Oxford University. He is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the European Academy of Cancer Science, the Lister Institute and Professorial Fellow of Linacre College Oxford. He has over 200 publications and is an inventor on an extensive number of patents.
Professor David Kerr
CBE MA MD DSc FRCP FRCGP FACP FESMO FMedSci
Chief Medical Officer
David is a senior clinician with more than 30 years experience in cancer treatment. He has a strong record in clinical research and has built numerous life sciences companies over the years, including Cobra, Therexsys, Oxford Cancer Biomarkers, IngenOx and SynOx Therapeutics. David contributes to Oxford as Professor of Cancer Medicine and Consultant Medical Oncologist, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He is an Honorary Professor of Oncology in Sichuan, Suchow, Xiamen, Shanghai, Zhejiang and Oslo Universities. He has published over 400 papers and has an H-Index > 100 associated with over 50,000 citations, placing him in the top 1-2% of cancer researchers in the world. He was elected President of the European Society of Medical Oncology in 2010. He is Editor in Chief of The Oxford Textbooks of Oncology and Cancer Biology, was Editor in Chief of Annals of Oncology, established the Journal of Global Oncology and leads a new course in Oxford on Global Health Diplomacy.
Bill Fleming
MA (Law) ACMA
Chief Financial Officer
Bill’s career spans over 25 years in a broad range of operational roles. Holding a law degree from Cambridge University and as a qualified ACMA, Bill has accumulated international FD/CFO experience in small venture-backed companies and large blue chips. Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics, subsequently holding senior finance positions for Bayer Healthcare in Europe and the USA. Bill played a leading role in securing investment for Oxford University spinout Oxitec and in its successful acquisition by Intrexon Corporation. Bill actively supports the Biotech industry with roles including Chair of OBN, and engagements with IngenOx Therapeutics, Grey Wolf Therapeutics and Ultromics Ltd.
Collette Coll
MBA
Operations Director
Collette is a qualified and experienced business leader. She has held several management positions in both industry and academia throughout her career. Collette has held Operations Director positions in a number of University of Oxford spin-out companies over much of the past decade. She demonstrates leadership in strategic planning and implementation of cross-functional corporate and business activities.
Shonagh Munro
PhD
Research Director
Shonagh has two decades of scientific research experience, initially at the University Dundee where she gained a PhD in biochemistry, then subsequently at the University of Oxford where she undertook postdoctoral studies in the Department of Oncology. She brings to the company a deep biological understanding and key technological expertise. She has numerous high-impact publications focusing on the mechanisms of cancer cell growth and death. In her role as research director at IngenOx she leads the scientific team in discovering and developing new precision cancer therapeutics.
Simon Cook
MSc CSci MIBMS
Clinical Research Director
Simon Cook is a Chartered Scientist and Member of the Institute of Biomedical Sciences, with 36 years of experience in running international clinical trials in all phases (I-IV). Initially graduating in Pharmacology from the University of Strathclyde, he has since become a specialist in the management of commercial drug development to GCP standards and has written two books on the subject. He began his career with manufacturers such as Beechams (now GSK) and then crossed into the CRO business: managing clinical trials at companies such as G H Besselaar Associates (now Covance), Quintiles (now IQVIA), and Kendle International (now Syneos Health). Since 2016 he has specialised in researching novel anti-cancer agents within the biotech sector, at IngenOx Therapeutics, Oxford; and latterly SynOx Therapeutics.
Shawn S Zheng
DPhil MBA FRSB
SVP, Business and Innovation
Shawn is a management professional with extensive scientific and business experience across multiple Oxford University spinouts, including IngenOx, Celleron, Argonaut, and SynOx Therapeutics. He was a principal investigator at MSD / A*STAR where he led a cancer drug discovery programme and published articles in top-tier research journals listed in the Nature Index. Shawn received his DPhil / PhD in Oncology at the University of Oxford and underwent post-doctoral training with Sir David Lane FRS. He received his MBA from the Judge Business School at the University of Cambridge, specialising in biopharma management. He is a Visiting Researcher at the Department of Oncology, University of Oxford and an elected Fellow of the Royal Society of Biology.
Board of Directors
James Noble
Chairman
James Noble MA FCA has held a number of high-profile positions in his long and successful career in the Biotech sector, most recently as Co-Founder and CEO of Adaptimmune Therapeutics. He was also the founding CEO of Immunocore Ltd. James currently serves as a non-executive director of Adaptimmune and is Deputy Chairman of NASDAQ-listed GW Pharmaceuticals. Prior to that, James held a wide range of non-executive roles, including on the Boards of Medigene, Powderject and Oxford Glycosciences. He was previously CFO at British Biotech, where he took the company public in London and on NASDAQ and was formerly a director at the investment bank, Kleinwort Benson. James has extensive experience of both private and public sector markets.
Bill Fleming
MA (Law) ACMA
Chief Financial Officer
Bill’s career spans over 25 years in a broad range of finance positions. Holding a law degree from Cambridge University and as a qualified ACMA, Bill has accumulated international FD/CFO experience in small venture-backed companies and large blue chips. Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics, subsequently holding senior finance positions for Bayer Healthcare in Europe and the USA. Bill played a leading role in securing investment for Oxford University spinout Oxitec and in its successful acquisition by Intrexon Corporation. Bill actively supports the Biotech industry with roles including Chair of OBN, and engagements with IngenOx Therapeutics, Grey Wolf Therapeutics and Ultromics Ltd.
Simon Kerry
MBA
Non-Executive Director
Dr Kerry is co-founder of Curve Therapeutics and an experienced life-science entrepreneur with over 30 years in leadership roles within European biotechnology companies. He has been an Operating Partner at Advent Life Sciences, a leading trans-Atlantic venture investor, since 2017. Prior to joining Advent, Simon was CEO of cancer drug discovery company Karus Therapeutics (Oxford, UK), leading the company from spin-out to clinic. Before Karus, Simon led the Business Development functions at Ablynx (Ghent, Belgium), Active Biotech (Lund, Sweden) and Isogenica (Cambridge, UK). Following a first degree in Medicinal and Pharmaceutical Chemistry (1984), Simon began his career as a chemist at GD Searle (High Wycombe, UK). He completed a life-science PhD in 1989 and obtained an Executive MBA from Loughborough University Business School in 1995.
Nick Dixon-Clegg
MA (Cantab)
Investor Director
Mr Dixon-Clegg is Head of Independent Investments at Oxford Science Enterprises (OSE). He joined OSE in July 2020, bringing a decade of investment and corporate finance experience. He is responsible for managing a number of portfolio companies, supporting their growth and development, and investing fresh capital. As part of his role, he serves as a Director on the boards of Argonaut Therapeutics, BibliU, Circadian Therapeutics, Dark Blue Therapeutics, EnzBond, Iota Sciences, Metaboards and Opsydia, and additionally holds a number of board observer positions. Prior to Oxford Science Enterprises, Nick was an Investment Principal at Valiance, a MedTech-focused venture capital firm. He has also held roles as an investor at Nordic Capital and started his career as an investment banker at Bank of America Merrill Lynch. Nick has a Triple First Class MA (Cantab) in Natural Sciences from the University of Cambridge.
Professor Nick La Thangue
MA MSc PhD FRSE FMedSci
Chief Executive Officer
Nick has over 30 years of experience in biotech entrepreneurship, translational cancer science and drug development. He founded Prolifix focused on cell cycle therapeutics, where he acted as CSO and CEO until its merger with TopoTarget which led to a highly successful IPO. He founded Oxford Cancer Biomarkers, which continues to develop a portfolio of marketed precision cancer medicine tests, where he held senior positions including CEO and CSO. He has been CEO at IngenOx Therapeutics developing precision cancer drugs since the company was founded. Nick is Professor of Cancer Biology at Oxford University. He is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the European Academy of Cancer Science, the Lister Institute and Professorial Fellow of Linacre College Oxford. He has over 200 publications and is an inventor on numerous patents.
Professor David Kerr
CBE MA MD DSc FRCP FRCGP FACP FESMO FMedSci
Chief Medical Officer
David is a senior clinician with more than 30 years experience in cancer treatment. He has a strong record in clinical research and has built numerous life sciences companies over the years, including Cobra, Therexsys, Oxford Cancer Biomarkers, IngenOx and SynOx Therapeutics. David contributes to Oxford as Professor of Cancer Medicine, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He is an Honorary Professor of Oncology in Sichuan, Suchow, Xiamen, Shanghai, and Seoul National Universities. He has published over 400 papers and has an H-Index of 95 associated with over 45,000 citations. He was elected President of the European Society of Medical Oncology in 2010. He is Editor in Chief of The Oxford Textbooks of Oncology and Cancer Biology, was Editor in Chief of Annals of Oncology, established the Journal of Global Oncology and has initiated a new course in Oxford on Global Health Diplomacy.
Strategic Collaborations
Global Pharma
IngenOx has acquired global rights to zabinostat (CXD101) through an exclusive world-wide license agreement from AstraZeneca
SynOx Therapeutics (an IngenOx spin-out) has acquired global rights to emactuzumab through an exclusive world-wide license agreement from Roche
Asian Healthcare
IngenOx has a sub-licensing and partnership agreement with Nuance Biotech to develop zabadinostat in China and South Africa
IngenOx has signed a memorandum of understanding (MOU) with Genor Biopharma relevant to the clinical development of zabadinostat
Oxford
IngenOx has established a unique partnership with Oxford University Hospitals NHS Trust to facilitate its clinical trials and develop its precision medicine platform
SynOx Therapeutics
SynOx Therapeutics is an IngenOx spin-out with a focus to deliver marketing approval for emactuzumab in diffuse tenosynovial giant cell tumour.
In December 2020, SynOx acquired a world-wide exclusive license for emactuzumab from Roche, and received €37 million investment from HealthCap, Medicxi, Forbion and Gimv.